Baltimore News Journal – Lifestyle
Author:
NurExone Biologic Inc
NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026
May 14, 2026
Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production
April 27, 2026
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
April 16, 2026
NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization
April 7, 2026
NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy
April 1, 2026
NurExone Announces Corporate Updates
March 11, 2026